{Reference Type}: Multicenter Study
{Title}: Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis.
{Author}: Lemelle L;Guillemot D;Hermann AL;Gauthier A;Carton M;Corradini N;Rome A;Berlanga P;Jourdain A;Marie Cardine A;Jannier S;Boutroux H;Defachelles AS;Aerts I;Geoerger B;Karanian M;Doz F;Brisse HJ;Schleiermacher G;Delattre O;Pierron G;Orbach D;
{Journal}: Expert Rev Anticancer Ther
{Volume}: 23
{Issue}: 8
{Year}: 2023 Jul-Dec 1
{Factor}: 3.627
{DOI}: 10.1080/14737140.2023.2236305
{Abstract}: NTRK gene fusions have been identified in various tumors; some requiring aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a national, unselected, retrospective, multicenter cohort.<BR>Patients were identified through the French sarcoma diagnostic laboratory at Institut Curie through samples analyzed by RT-qPCR or whole-transcriptome sequencing.<BR>From 2001 to 2019, 65 NTRK fusion tumors were identified within 2120 analyses (3.1%): 58 by RNA sequencing (including 20 after RT-qPCR analysis) and 7 exclusively by RT-qPCR. Of the 61 patients identified, 37 patients had infantile soft tissue or kidney fibrosarcomas (IFS), 15 other mesenchymal (Other-MT) and nine central nervous system (CNS) tumors. They encompassed 14 different tumor types with variable behaviors. Overall, 53 patients had surgery (3 mutilating), 38 chemotherapy (20 alkylating agents/anthracycline), 11 radiotherapy, two 'observation strategy' and 13 received TRKi. After a median follow-up of 61.0 months [range, 2.5-226.0], 10 patients died. Five-year overall survival is, respectively, 91.9% [95%CI, 83.5-100.0], 61.1% [95%CI, 34.2-100.0] and 64.8% [95%CI, 39.3-100.0] for IFS, Other-MT, and CNS groups.<BR>NTRK-fusion positive tumors are rare but detection is improved through RNA sequencing. TRKi could be considered at diagnosis for CNS NTRK-fusion positive tumors, some IFS, and Other-MT.<BR>Not adapted.